Niosomes as target drug delivery system: A review

Abstract

The formulation of vesicles as a way of improving the delivery of drugs over the past several years has generated a lot of concern among scientists working in the field of drug delivery systems. The vesicular niosomal system is capable of increasing the bioavailability of a product. When its bilayer structure is constructed by non-ionic surfactants, the bioavailability of products to a specified region for an extended period. Niosomes and liposomes are equative in drug delivery capacity, and both have decreased drug usefulness regarding free drug use. Niosomes are contrasted with liposomes when the high chemical stability and efficacy of the substitute are considered. For medicines and therapeutic purposes, the implementation of vesicular (lipid vesicles and nonionic surfactant vesicles) devices can give many benefits. They strengthen drug molecules ’ clinical efficiency by delaying clearance from circulation, safeguarding the drug from the genetic atmosphere, and limiting target cell impacts. This study focused on recent developments in the distribution for niosomal medicines, possible benefits above other delivery systems, methods of construction, characterisation methods, and current niosome studies. Niosome seems to be a system of choice of drug delivery over liposome as a stable and economical niosome. Niosomes often have tremendous potential for nanotechnology to achieve focused non-cancer, non-infective agents. Niosome’s potential for drug delivery can be improved using new ideas such as proniosomes, discomes, and aspasome. Niosomes are also useful for diagnostic testing and as an active ingredient to the vaccine. Such areas, therefore, need additional study and development to products available in the market niosomal preparations.